At 02:50 pm Divis Laboratories hits 52-week low of Rs 855, down 23% on the BSE in intra-day trade on back of heavy volumes.
On December 7, 2016, the US Food and Drug Administration (USFDA) had issued form 483 with five observations against Divi's Laboratories' unit at Chippada Village in Visakhapatnam of Andhra Pradesh. The USFDA inspected the company’s unit from November 29, 2016 to December 6, 2016.
These critical observations will be responded within the time permitted, the company said in a statement.
Form 483 relates to certain critical observations issued to a company at the end of an inspection if there were any violations of the Food Drug and Cosmetic Act and other related acts of the US Government.
Divi's manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at this plant.
For More Updated Stock intraday Trading Tips, Visit us at
These critical observations will be responded within the time permitted, the company said in a statement.
Form 483 relates to certain critical observations issued to a company at the end of an inspection if there were any violations of the Food Drug and Cosmetic Act and other related acts of the US Government.
Divi's manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at this plant.
For More Updated Stock intraday Trading Tips, Visit us at
Zoid Research
Office 101, Shagun Tower
A.B. Commercial Road, Indore
Office 101, Shagun Tower
A.B. Commercial Road, Indore
452001
Website: www.zoidresearch.com
Mobile:
+91 9039073611
Email: info@zoidresearch.com
Mobile:
+91 9039073611Email: info@zoidresearch.com
